Request Information

Now FDA Approved - New Patient Starting Dose

Calculate now

The best parts of life rarely follow a plan

Insulin the moment

We encourage you to review the full 2026 ADA Standards of Care and consider how inhaled insulin can be integrated into your practice. View the guidelines

We encourage you to review the full 2026 ADA Standards of Care and consider how inhaled insulin can be integrated into your practice.

Proven A1C control1,2

AFREZZA® effectively lowers A1C in T1D and T2D patients

Fewer mealtime excursions3

AFREZZA significantly decreases PPG excursions after meals

STAT study
A1C=glycated hemoglobin; PPG=postprandial glucose; SC RAI=subcutaneous rapid-acting insulin; T1D=type 1 diabetes; T2D=type 2 diabetes.

References: 1. Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care. 2015;38(12):2274-2281. 2. Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38(12):2266-2273. 3. Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther. 2018;20(10):639-647.

© MannKind Corporation January, 2026. US-AFR-2792

Indications and Usage

Afrezza® (insulin human) Inhalation Powder is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis, not recommended in patients who smoke or have recently stopped smoking.

Important Safety Information for Afrezza® (insulin human) Inhalation Powder

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE. Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.